Forbion European Acquisition in a regulatory filing said its shareholders voted in favor of combinine wirh therapeutics company enGene.
As announced in May, the deal included $135 million in financing plus the SPAC’s $111 million in trust at that time. However, Forbion European in the filing disclosed that 10,379,144 Class A shares were redeemed ahead of the merger vote, removing most of the cash in trust.
enGene is advancing its immune-oncology platform, which includes its clinical-stage lead candidate detalimogene voraplasmid (EG-70), a non-viral gene therapy.
The transaction is expected to close Oct. 31, pending the satisfaction or waiver of closing conditions. Read more.
